Trump’s Prescription Drug Policy: Rhetoric vs. True Reform
Katherine O'Malley October 29, 2025
Trump’s drug pricing policy promises headlines but not savings – Americans still pay triple, while real reform remains out of reach.
Trump’s drug pricing policy promises headlines but not savings – Americans still pay triple, while real reform remains out of reach.
Prescription drug costs in America are too high – will Congress rein in the middlemen in the supply chain that contribute to this problem?
Cutting federal funding for the 9,000 public libraries serving as vital, local health hubs would negatively impact communities.
The Trump is cutting the health care coverage, programs, and infrastructure older Americans rely on.
Pharmacy benefit managers (PBMs) have recently been the focus of media and legislation, but what do they actually do?
Improving dementia care coordination will help patients and caregivers, reduce health care use, and lower costs.
Recent FDA staff cuts could lead to decreased oversight of pet food safety, increasing risks of contamination and recalls.
Federally-funded research on Alzheimer’s and dementia are on the chopping block.
Assessments of the effectiveness and cost-effectiveness of palliative care are often muddled by confounding and selection bias.
Players, coaches, and football fans conflate the use of new protective equipment with brain injury prevention—a feat no piece of equipment can achieve.
The Biden administration’s Inflation Reduction Act laid the foundation for relief from prescription drug prices for millions of Americans, but the Trump administration may thwart its progress.
A new policy brief from PEPReC highlights the relationship between physician base salary and time to fill at the Veterans Health Administration.